Potential for novel MUC1 glycopeptide-specific antibody in passive cancer immunotherapy

Immunopharmacology and Immunotoxicology

Volumn 35, Issue 6, 2013, Pages 649-652

  Madsen, Caroline B ^a,b   Wandall, Hans H ^a   Pedersen, Anders Elm ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

ADCC; Antibody; Immunotherapy; MUC1; NK cell

Indexed keywords

ALPHA INTERFERON; EPITOPE; GLYCOPEPTIDE; INTERLEUKIN 2; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 5E5; MUCIN 1; PANKOMAB; UNCLASSIFIED DRUG;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CELL; CANCER IMMUNOTHERAPY; CANCER PATIENT; CROSS REACTION; DRUG POTENCY; DRUG TARGETING; HUMAN; NATURAL KILLER CELL; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTIBODIES, NEOPLASM; EPITOPES; HUMANS; IMMUNIZATION, PASSIVE; MUCIN-1; NEOPLASMS;

EID: 84887864047     PISSN: 08923973     EISSN: 15322513     Source Type: Journal    
DOI: 10.3109/08923973.2013.837060     Document Type: Review

References (57)

1. Kufe DW. Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer 2009;9:874-885.
2. Gendler SJ, Spicer AP, Lalani EN, et al. Structure and biology of a carcinoma-associated mucin, MUC1. Am Rev Respir Dis 1991; 144:S42-S47.
3. Tarp MA, Clausen H. Mucin-type O-glycosylation and its potential use in drug and vaccine development. Biochim Biophys Acta 2008; 1780:546-563. (Pubitemid 351381249)
4. Hollingsworth MA, Swanson BJ. Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer 2004;4:45-60. (Pubitemid 38082153)
5. Hanisch FG. O-glycosylation of the mucin type. Biol Chem 2001; 382:143-149.
6. Ju T, Aryal RP, Kudelka MR, et al. The Cosmc connection to the Tn antigen in cancer. Cancer Biomarkers, submitted.
7. Gill DJ, Chia J, Senewiratne J, Bard F. Regulation of O-glycosylation through Golgi-to-ER relocation of initiation enzymes. J Cell Biol 2010;189:843-858.
8. Nicholson S, Bomphray CC, Thomas H, et al. A phase I trial of idiotypic vaccination with HMFG1 in ovarian cancer. Cancer Immunol Immunother 2004;53:809-816. (Pubitemid 39149908)
9. Oei AL, Verheijen RH, Seiden MV, et al. Decreased intraperitoneal disease recurrence in epithelial ovarian cancer patients receiving intraperitoneal consolidation treatment with yttrium-90-labeled murine HMFG1 without improvement in overall survival. Int J Cancer 2007;120:2710-2714. (Pubitemid 46651295)
10. Oei AL, Moreno M, Verheijen RH, et al. Induction of IgG antibodies to MUC1 and survival in patients with epithelial ovarian cancer. Int J Cancer 2008;123:1848-1853.
11. Shimizu M, Imai M. Effect of the antibody immunotherapy by the anti-MUC1 monoclonal antibody to the oral squamous cell carcinoma in vitro. Biol Pharm Bull 2008;31:2288-2293.
12. Ibrahim NK, Yariz KO, Bondarenko I, et al. Randomized phase II trial of letrozole plus anti-MUC1 antibody AS1402 in hormone receptor-positive locally advanced or metastatic breast cancer. Clin Cancer Res 2011;17:6822-6830.
13. Pegram MD, Borges VF, Ibrahim N, et al. Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancer. Breast Cancer Res 2009;11:R73 (1-8).
14. Mobus VJ, Baum RP, Bolle M, et al. Immune responses to murine monoclonal antibody-B43.13 correlate with prolonged survival of women with recurrent ovarian cancer. Am J Obstet Gynecol 2003;189:28-36. (Pubitemid 36886520)
15. Noujaim AA, Schultes BC, Baum RP, Madiyalakan R. Induction of CA125-specific B and T cell responses in patients injected with MAb-B43.13 - evidence for antibody-mediated antigen-processing and presentation of CA125 in vivo. Cancer Biother Radiopharm 2001;16:187-203. (Pubitemid 32641217)
16. Garkavij M, Samarzija M, Ewers SB, et al. Concurrent radiotherapy and tumor targeting with 111In-HMFG1-F(ab0)2 in patients with MUC1-positive non-small cell lung cancer. Anticancer Res 2005; 25:4663-4671. (Pubitemid 41729528)
17. Wang L, Chen H, Pourgholami MH, et al. Anti-MUC1 monoclonal antibody (C595) and docetaxel markedly reduce tumor burden and ascites, and prolong survival in an in vivo ovarian cancer model. PLoS One 2011;6:e24405.
18. Wang L, Chen H, Liu F, et al. Monoclonal antibody targeting MUC1 and increasing sensitivity to docetaxel as a novel strategy in treating human epithelial ovarian cancer. Cancer Lett 2011;300: 122-133.
19. Verheijen RH, Massuger LF, Benigno BB, et al. Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission. J Clin Oncol 2006;24: 571-578. (Pubitemid 46655592)
20. Song YJ, Qu CF, Rizvi SM, et al. Cytotoxicity of PAI2, C595 and Herceptin vectors labeled with the alpha-emitting radioisotope Bismuth-213 for ovarian cancer cell monolayers and clusters. Cancer Lett 2006;234:176-183.
21. Qu CF, Li Y, Song YJ, et al. MUC1 expression in primary and metastatic pancreatic cancer cells for in vitro treatment by (213)Bi-C595 radioimmunoconjugate. Br J Cancer 2004;91: 2086-2093. (Pubitemid 40128776)
22. Gordon AN, Schultes BC, Gallion H, et al. CA125-and tumorspecific T-cell responses correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patients. Gynecol Oncol 2004;94:340-351. (Pubitemid 39024536)
23. Braly P, Nicodemus CF, Chu C, et al. The Immune adjuvant properties of front-line carboplatin-paclitaxel: A randomized phase 2 study of alternative schedules of intravenous oregovomab chemoimmunotherapy in advanced ovarian cancer. J Immunother 2009;32:54-65.
24. Berek JS, Taylor PT, Gordon A, et al. Randomized, placebocontrolled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. J Clin Oncol 2004;22:3507-3516. (Pubitemid 41103657)
25. Snijdewint FG, von Mensdorff-Pouilly S, Karuntu-Wanamarta AH, et al. Antibody-dependent cell-mediated cytotoxicity can be induced by MUC1 peptide vaccination of breast cancer patients. Int J Cancer 2001;93:97-106. (Pubitemid 32539508)
26. Moreno M, Bontkes HJ, Scheper RJ, et al. High level of MUC1 in serum of ovarian and breast cancer patients inhibits huHMFG-1 dependent cell-mediated cytotoxicity (ADCC). Cancer Lett 2007; 257:47-55. (Pubitemid 47464696)
27. Pichinuk E, Benhar I, Jacobi O, et al. Antibody targeting of cellbound MUC1 SEA domain kills tumor cells. Cancer Res 2012;72: 3324-3336.
28. Salouti M, Babaei MH, Rajabi H, Rasaee M. Preparation and biological evaluation of (177)Lu conjugated PR81 for radioimmunotherapy of breast cancer. Nucl Med Biol 2011;38:849-855.
29. Mohammadnejad J, Rasaee MJ, Babaei MH, et al. Radioimmunotherapy of MCF7 breast cancer cell line with 131IPR81 monoclonal antibody against MUC1: comparison of direct and indirect radioiodination methods. Hum Antibodies 2010;19:15-25.
30. Paknejad M, Rasaee MJ, Tehrani FK, et al. Production of monoclonal antibody, PR81, recognizing the tandem repeat region of MUC1 mucin. Hybrid Hybridomics 2003;22:153-158. (Pubitemid 37011792)
31. Schettini J, Kidiyoor A, Besmer DM, et al. Intratumoral delivery of CpG-conjugated anti-MUC1 antibody enhances NK cell anti-tumor activity. Cancer Immunol Immunother 2012;61:2055-2065.
32. Mohammadi M, Rasaee MJ, Rajabibazl M, et al. Epitope mapping of PR81 anti-MUC1 monoclonal antibody following PEPSCAN and phage display techniques. Hybridoma (Larchmt) 2007;26: 223-230.
33. Wandall HH, Blixt O, Tarp MA, et al. Cancer biomarkers defined by autoantibody signatures to aberrant o-glycopeptide epitopes. Cancer Res 2010;70:1306-1313.
34. Wahrenbrock MG, Varki A. Multiple hepatic receptors cooperate to eliminate secretory mucins aberrantly entering the bloodstream: Are circulating cancer mucins the ''tip of the iceberg'' Cancer Res 2006;66:2433-2441.
35. Tucker-Burden C, Chappa P, Krishnamoorthy M, et al. Lectins identify glycan biomarkers on glioblastoma-derived cancer stem cells. Stem Cells Dev 2012;21:2374-2386.
36. Curry JM, Thompson KJ, Rao SG, et al. The use of a novel MUC1 antibody to identify cancer stem cells and circulating MUC1 in mice and patients with pancreatic cancer. J Surg Oncol 2013;107:713-722.
37. Danielczyk A, Stahn R, Faulstich D, et al. PankoMab: A potent new generation anti-tumour MUC1 antibody. Cancer Immunol Immunother 2006;55:1337-1347. (Pubitemid 44187665)
38. Marcos NT, Cruz A, Silva F, et al. Polypeptide GalNAc-transferases, ST6GalNAc-transferase I, and ST3Gal-transferase I expression in gastric carcinoma cell lines. J Histochem Cytochem 2003; 51:761-771. (Pubitemid 36628857)
39. Hanisch FG, Stadie T, Bosslet K. Monoclonal antibody BW835 defines a site-specific Thomsen-Friedenreich disaccharide linked to threonine within the VTSA motif of MUC1 tandem repeats. Cancer Res 1995;55:4036-4040.
40. Jeschke U, Wiest I, Schumacher AL, et al. Determination of MUC1 in sera of ovarian cancer patients and in sera of patients with benign changes of the ovaries with CA15-3, CA27.29, and PankoMab. Anticancer Res 2012;32:2185-2189.
41. Fan XN, Karsten U, Goletz S, Cao Y. Reactivity of a humanized antibody (hPankoMab) towards a tumor-related MUC1 epitope (TA-MUC1) with various human carcinomas. Pathol Res Pract 2010;206:585-589.
42. Dian D, Janni W, Kuhn C, et al. Evaluation of a novel anti-mucin 1 (MUC1) antibody (PankoMab) as a potential diagnostic tool in human ductal breast cancer; comparison with two established antibodies. Onkologie 2009;32:238-244.
43. Pedersen JW, Blixt O, Bennett EP, et al. Seromic profiling of colorectal cancer patients with novel glycopeptide microarray. Int J Cancer 2010;128:1860-1871.
44. Tarp MA, Sorensen AL, Mandel U, et al. Identification of a novel cancer-specific immunodominant glycopeptide epitope in the MUC1 tandem repeat. Glycobiology 2007;17:197-209. (Pubitemid 46152536)
45. Sorensen AL, Reis CA, Tarp MA, et al. Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance. Glycobiology 2006;16:96-107. (Pubitemid 43125966)
46. Van Elssen CH, Frings PW, Bot FJ, et al. Expression of aberrantly glycosylated Mucin-1 in ovarian cancer. Histopathology 2010;57: 597-606.
47. Lavrsen K, Madsen CB, Rasch MG, et al. Aberrantly glycosylated MUC1 is expressed on the surface of breast cancer cells and a target for antibody-dependent cell-mediated cytotoxicity. Glycoconj J 2012;30:227-236.
48. Dunne J, Lynch S, O'Farrelly C, et al. Selective expansion and partial activation of human NK cells and NK receptor-positive T cells by IL-2 and IL-15. J Immunol 2001;167:3129-3138. (Pubitemid 32852551)
49. Herberman RB, Ortaldo JR, Mantovani A, et al. Effect of human recombinant interferon on cytotoxic activity of natural killer (NK) cells and monocytes. Cell Immunol 1982;67:160-167. (Pubitemid 12189638)
50. Roda JM, Parihar R, Lehman A, et al. Interleukin-21 enhances NK cell activation in response to antibody-coated targets. J Immunol 2006;177:120-129. (Pubitemid 43939123)
51. Roda JM, Joshi T, Butchar JP, et al. The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines. Clin Cancer Res 2007;13:6419-6428. (Pubitemid 350075032)
52. Mukherjee P, Pathangey LB, Bradley JB, et al. MUC1-specific immune therapy generates a strong anti-tumor response in a MUC1-tolerant colon cancer model. Vaccine 2007;25: 1607-1618. (Pubitemid 46108207)
53. Tinder TL, Subramani DB, Basu GD, et al. MUC1 enhances tumor progression and contributes toward immunosuppression in a mouse model of spontaneous pancreatic adenocarcinoma. J Immunol 2008;181:3116-3125.
54. Ghosh SK, Uchida M, Yoo B, et al. Targeted imaging of breast tumor progression and therapeutic response in a human uMUC-1 expressing transgenic mouse model. Int J Cancer 2013;132: 1860-1867.
55. Heuser C, Ganser M, Hombach A, et al. An anti-MUC1-antibody-interleukin-2 fusion protein that activates resting NK cells to lysis of MUC1-positive tumour cells. Br J Cancer 2003; 89:1130-1139. (Pubitemid 37243025)
56. Reddy PK, Gold DV, Cardillo TM, et al. Interferon-gamma upregulates MUC1 expression in haematopoietic and epithelial cancer cell lines, an effect associated with MUC1 mRNA induction. Eur J Cancer 2003;39:397-404. (Pubitemid 36140059)
57. Pule M, Finney H, Lawson A. Artificial T-cell receptors. Cytotherapy 2003;5:211-226.